SCM
KTTA icon

Stonepine Capital Management’s Pasithea Therapeutics KTTA Stock Holding History

Stonepine Capital Management’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$617K Buy
831,301
+556,239
+202% +$465K 0.25% 52
2025
Q4 		$355K Buy
+275,062
New +$242K 0.26% 54

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stonepine Capital Management's KTTA Position: Q1 2026 in Review

Stonepine Capital Management increased its Pasithea Therapeutics (KTTA) stake by 202% in Q1 2026, buying an estimated $465K and bringing the position to 831,301 shares worth $617K. The position accounts for 0.25% of the portfolio, ranked #52.

Stonepine Capital Management first reported a position in KTTA in Q4 2025 and has held it in 2 quarters since. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Stonepine Capital Management held 831,301 shares of Pasithea Therapeutics worth $617K as of Q1 2026.
  • Stonepine Capital Management bought 556,239 Pasithea Therapeutics shares in Q1 2026, an estimated $465K.
  • Pasithea Therapeutics made up 0.25% of Stonepine Capital Management's portfolio in Q1 2026, its #52 holding.
  • Stonepine Capital Management first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.